Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder
Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder
复制标题
DOI：
10.1097/yic.0b013e328303ac5f
复制
发表时间：
2008-09-01
影响因子：
2.6
通讯作者：
Reines, Elin Heldbo
中科院分区：
文献类型：
--
作者：
Dernyttenaere, Koen;Andersen, Henning Friis;Reines, Elin Heldbo
在治疗前后对重度抑郁症（MDD）和广泛性焦虑症（GAD）进行相同的生活质量享受和满意度调查问卷（Q-LES-Q），使我们能够比较这两种疾病的生活质量享受和满意度，并比较基于症状与功能的结果。使用来自八项随机、为期 8 周、双盲、安慰剂对照艾司西酞普兰临床试验的 Q-LES-Q 和症状特异性蒙哥马利-阿斯伯格抑郁评定量表 (MADRS) 和汉密尔顿焦虑量表 (HAMA) 数据。 MDD (n = 1140) 或 GAD (n = 1045) 患者报告生活质量享受和满意度严重受损（基线分数分别为社区标准的 64% 和 76%）。治疗使生活质量和满意度在统计和临床上显着改善。使用艾司西酞普兰治疗的患者的改善效果优于安慰剂治疗的患者。在 MDD 中，大多数汇款人 (MADRS
Administration of the same Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) in major depressive disorder (MDD) and in generalized anxiety disorder (GAD) before and after treatment allowed us to compare quality of life enjoyment and satisfaction in these two disorders and to compare outcome based on symptoms versus functioning. Q-LES-Q and symptom-specific Montgomery-Asberg Depression Rating Scale (MADRS) and Hamilton Anxiety Scale (HAMA) data from eight randomized, 8-week, double-blind, placebo-controlled clinical trials with escitalopram were used. MDD (n = 1140) or GAD (n = 1045) patients report a substantial degree of quality of life enjoyment and satisfaction impairment (baseline scores 64% and 76% of community norm, respectively). Treatment resulted in statistically and clinically significant improvement in quality of life enjoyment and satisfaction. The improvement was greater in patients treated with escitalopram than with placebo. In MDD, the majority of remitters (MADRS